← Emergent Ventures Africa HIGH Neuropharm/CCT
Programme Research
Emergent Ventures Africa · Mercatus Center / Tyler Cowen
Programme Site
HIGH confidence Researched 2026-07-09 17:43 · profile: researcher
Emergent Ventures (Africa & Caribbean vertical) funds individuals with genuinely 'zero to one' ideas that advance prosperity, liberty, or wellbeing — projects so novel and high-upside that mainstream funders would never back them. Launched June 2023, the Africa track is managed by Rasheed Griffith (himself an EV recipient) under Tyler Cowen's direction with Schmidt Futures backing, and runs on the same philosophy as the parent programme: fast, low-bureaucracy bets on people over credentials. It exists because Tyler Cowen believes the best mechanism for driving human progress is finding exceptional individuals early and getting out of their way.
• Zero-to-one framing: the idea must create something genuinely new — not iterative improvement on existing work • Scalability potential: the project must be able to affect many people, not just a local audience • Personal narrative coherence: the applicant's backstory must meaningfully connect to and explain why they are the right person for this specific project • Reverse-contrarianism signal: applicants must answer 'one mainstream view you agree with' — tested specifically to distinguish people with real intellectual courage from reflexive contrarians • Revenue or self-sufficiency path: explicitly favoured ('a quick path to revenue self-sufficiency is a feature, not a bug') • Unconventional background or non-institutional positioning is a plus, not a minus — Tyler is actively looking for people outside normal credentialling pipelines • Africa/Caribbean geographic nexus: the Africa track prioritises proposals that are clearly rooted in or benefit the African/Caribbean context • Minimum eligibility: age 13+; no nationality, credential, or sector restrictions • Proposal length: ≤1500 words; must stand on its own before supplementary materials are reviewed • Note: supplementary file uploads do NOT accept PDFs — all preprints and papers must be linked as URLs/multimedia links
The Africa & Caribbean track has now run 7 cohorts (through Nov 2025). Winner archetypes span: (a) researchers using a grant to access a global institution they could not otherwise reach (Emmanuel Nnadi, Nigeria, phage therapy visiting research at Waterloo; Jibrin Jaafaru, Nigeria, bioinformatics fellowship in the US; Rupert Tawiah-Quashie, Ghana, Harvard internship on symbolic reasoning in AI); (b) builders creating first-of-kind infrastructure or products for the continent (Mercy Muwanguzi/Kwesiga Pather, Uganda, sanitation robotics; Abdoulaye Faye, Senegal, remotely operated robot firm; Rose Mutiso, Kenya, African Tech Futures Lab for energy policy); (c) career development and travel grants for exceptional students and early-career researchers (Tony Odhiambo, Kenya/MIT, math olympiad training; Isaac Akintaro, Nigeria/England CS PhD, Silicon Valley travel; Katharine Patterson, Botswana, NASA JPL robotics internship); (d) institution-builders creating intellectual infrastructure Africa lacks (Phumiani Majozi, South Africa, classical liberal think tank; Ken Opalo, blogging on African economic development). Nigeria is prominently represented in recent cohorts. Science and computational research are recurring themes — bioengineering (Michael Konu, virtual cells), mRNA optimisation (Joshua Payne), bioinformatics (Jibrin Jaafaru), and AI (Rupert Tawiah-Quashie). Grant sizes are unstated publicly but understood to range from travel stipends to $50K+.
The platonic EV Africa applicant is a high-agency individual at the frontier of their field who is visibly the only person likely to do this particular thing — someone operating outside traditional institutional pipelines (or despite them) who can articulate in ≤1500 words a clear personal narrative explaining why they exist at this intersection, what genuinely new thing they are building, and why Africa specifically needs it. They have already started — there is evidence of execution, not just a plan. Tyler Cowen personally reads every application and is specifically attracted to people who demonstrate unusual intellectual self-directedness and have an unconventional route to a problem that others missed.
Eniola's strongest angle is the infrastructural zero-to-one claim: she is not just a scientist — she is building the first computational pharmacology stack for a continent that has none, and the CCT model is its theoretical engine. The application should open with the institutional void (Africa's complete absence of CNS drug-discovery capacity) and position the CCT not as 'a new addiction model' but as a first-principles correction to why 60 years of dopamine-targeting addiction pharmacology has failed — with a validated mathematical substrate, pre-registered hypotheses now confirmed, and a provisional patent as the revenue path. The three platforms (IMPRINT, TOPOLOGIX, GATE) are not side projects; they are what makes her irreplaceable: she is the only person assembling this stack from a Lagos VPS with elite collaborators at Michigan, Harvard, Princeton, and NYU. The application's personal narrative section should foreground the fact that she built all of this as an independent researcher with zero institutional funding or lab access — exactly the kind of unconventional trajectory Tyler Cowen rewards.
• Supplementary file uploads on the EV form do NOT accept PDFs — Eniola must link all three preprints and her platforms via the Multimedia URL field and in-text hyperlinks, not uploaded files • The 1500-word cap is tight for a project this technically dense — she must resist explaining the CCT mechanism and instead sell the vision and her uniqueness; the preprint links do the technical heavy lifting • The 'one mainstream view you agree with' question is the highest-leverage section Tyler actually reads for signal — a weak or boilerplate answer (e.g. 'vaccines work') will sink an otherwise strong application; Eniola should use it to demonstrate her genuine epistemic confidence, not contrarianism • Her provisional patent is Q3 2026 (forthcoming, not filed) — she should reference it as 'patent pending / Q3 2026 filing' to signal commercialisation intent without overclaiming • She is not yet enrolled in a PhD — this is a feature not a bug for EV, but the application should proactively address it: frame independent research as intentional, not as a gap • The review article 'under review' at NBB is not yet accepted — she should describe it accurately ('under review') and not overstate its status
2026-07-09 17:31 · high confidence